# US 2014/0155324 A1 · Novel peptides and uses thereof in therapeutic methods > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155324 A1 - Document ID: US20140155324A1 - Status: Published application - Kind: A1 - Application number: 14/235,903 - Filed: 2012-08-06 - Published: 2014-06-05 - Earliest claimed: 2011-08-08 - Assignees: Two To Biotech Ltd. - Inventors: Tamara Sandler; Orly Devary - Web page: https://patentgrep.com/patent/US20140155324A1 ## CPC - C07K 14/47: from mammals - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 25/00: Drugs for disorders of the nervous system - A61P 37/02: Immunomodulators - C07K 14/4702: {Regulators; Modulating activity} - C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention relates to polypeptides exhibiting metabolic-modulating as well as immunomodulatory properties, nucleic acids encoding them, compositions comprising them, and methods of treating metabolic disorders and/or immune-related disorders comprising their administration and to their use in preparing pharmaceutical compositions for the treatment, amelioration, prophylaxis or delaying the onset of at least one of a metabolic disorder and an immune-related disorder. ## Claims ### Claim at position 1 1-49. (canceled) ### Claim 50 An isolated polypeptide comprising (a) the amino acid sequence set forth in SEQ ID NO: 1; (b) the amino acid sequence set forth in SEQ ID NO: 13; or (c) an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 or SEQ ID NO: 13. ### Claim 51 (depends on 50) The isolated polypeptide of claim 50, consisting of the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 13. ### Claim 52 (depends on 50) An isolated nucleic acid molecule comprising a sequence encoding the polypeptide of claim 50. ### Claim 53 (depends on 52) The isolated nucleic acid molecule of claim 52, comprising the nucleic acid sequence set forth in SEQ ID. NO. 2. ### Claim 54 (depends on 52) An expression vector comprising the nucleic acid molecule of claim 52. ### Claim 55 (depends on 54) A host cell transformed or transfected with the expression vector of claim 54. ### Claim 56 (depends on 50) A pharmaceutical composition comprising an isolated polypeptide according to claim 50 and at least one pharmaceutically acceptable carrier, diluent or excipient. ### Claim 57 A method for improving glucose metabolism in a subject suffering from a glucose metabolism related disorder, said method comprising administering an effective amount of an isolated polypeptide comprising (a) the amino acid sequence set forth in SEQ ID NO: 1; (b) the amino acid sequence set forth in SEQ ID NO: 13; or (c) an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 or SEQ ID NO: 13; or a pharmaceutical composition comprising the same. ### Claim 58 (depends on 57) The method of claim 57, wherein said glucose metabolism related disorder is associated with hyperglycemia. ### Claim 59 (depends on 58) The method of claim 58, wherein said glucose metabolism related disorder associated with hyperglycemia is selected from the group consisting of diabetes mellitus type I, diabetes mellitus type II, gestational diabetes, atherosclerosis, diabetic retinopathy, metabolic syndrome, immune-related disorders and cardiac disorders. ### Claim 60 (depends on 57) The method of claim 57, wherein said method improves glucose tolerance. ### Claim 61 (depends on 57) The method of claim 57, wherein said method reduces plasma glucagon. ### Claim 62 (depends on 57) The method of claim 57, wherein said method induces the expression of insulin receptors. ### Claim 63 (depends on 57) The method of claim 57, wherein said method increases the expression of GLUT-4 glucose transporter.